# A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

> **NCT00257478** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc**

## Conditions studied

- Prostate Cancer
- Cancer of Prostate
- Prostatic Cancer
- Cancer of the Prostate

## Interventions

- **DRUG:** YM155

## Key facts

- **NCT ID:** NCT00257478
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** — (—)
- **Last updated:** 2012-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257478, "A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00257478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*